-
公开(公告)号：US11840558B2
公开(公告)日：2023-12-12
申请号：US17357444
申请日：2021-06-24
申请人： AMGEN INC.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号： C07K14/05 , A61K38/1825 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US20210317176A1
公开(公告)日：2021-10-14
申请号：US17357444
申请日：2021-06-24
申请人： AMGEN INC.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US20180000898A1
公开(公告)日：2018-01-04
申请号：US15671923
申请日：2017-08-08
申请人： Amgen Inc.
IPC分类号： A61K38/18
CPC分类号： A61K38/1825
摘要： Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease
-
公开(公告)号：US20140323396A1
公开(公告)日：2014-10-30
申请号：US14167662
申请日：2014-01-29
申请人： AMGEN INC.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
IPC分类号： C07K14/50
CPC分类号： C07K14/50 , A61K38/00 , C07K2319/30
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
摘要翻译： 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。
-
公开(公告)号：US11072640B2
公开(公告)日：2021-07-27
申请号：US15996232
申请日：2018-06-01
申请人： AMGEN INC.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
摘要： The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
-
公开(公告)号：US20180280474A1
公开(公告)日：2018-10-04
申请号：US15765144
申请日：2016-09-30
申请人： AMGEN INC.
摘要： The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.
-
公开(公告)号：US20140243503A1
公开(公告)日：2014-08-28
申请号：US14134482
申请日：2013-12-19
申请人： Amgen Inc.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eav Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号： C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US10905772B2
公开(公告)日：2021-02-02
申请号：US15872841
申请日：2018-01-16
申请人： AMGEN INC.
发明人： Yuan Cheng , Chawita Netirojjanakul , Jerry Ryan Holder , Bin Wu , James R. Falsey , Bradley J. Herberich , Kelvin Sham , Leslie P. Miranda , Shu-Chen Lu , Murielle M. Veniant-Ellison , Shanaka Stanislaus , Junming Yie , Jing Xu
IPC分类号： A61K47/68 , A61K38/26 , A61P3/10 , C07K16/28 , A61K39/395
摘要： Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
-
公开(公告)号：US09273106B2
公开(公告)日：2016-03-01
申请号：US14134482
申请日：2013-12-19
申请人： Amgen Inc.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号： C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要： The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.
摘要翻译： 本发明提供具有降低的蛋白水解和聚集的FGF21突变体多肽，其包含其的药物组合物。
-
公开(公告)号：US20170233467A1
公开(公告)日：2017-08-17
申请号：US15518714
申请日：2015-10-16
申请人： AMGEN INC.
发明人： Shu-Chen Lu , Murielle M. Veniant-Ellison , Jing Xu , Hossein Salimi-Moosavi , Jonathan Daniel Oliner
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31 , C07K2317/55 , C07K2317/76
摘要： The present disclosure provides methods of treating ocular disorders using anti-angiogenic antibodies and pharmaceutical formulations.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.023 秒)
